Literature DB >> 3654884

Determination of sub-nanogram amounts of dihydroergotamine in plasma and urine using liquid chromatography and fluorimetric detection with off-line and on-line solid-phase drug enrichment.

H Humbert1, J Denouel, J P Chervet, D Lavene, J R Kiechel.   

Abstract

A highly sensitive and selective high-performance liquid chromatographic method, involving sample pre-treatment, column switching and fluorimetric detection, is described for the determination of dihydroergotamine in plasma and urine samples. The pre-chromatographic sample treatment consists of extraction by means of an Extrelut column for plasma samples, and pre-separation with enrichment steps on a Sep-Pak column for urine samples. The samples are then injected onto a pre-separation column (Aquapore), and the fraction containing dihydroergotamine are automatically diverted onto an analytical column (ODS reversed phase). An acetonitrile-ammonium carbamate gradient is used as the mobile phase. High recovery of dihydroergotamine from both plasma (87%) and urine (100%) and a detection limit as low as 100 pg/ml were achieved, with a linear response up to 5 ng/ml. The assay demonstrated a high degree of selectivity with regard to the extensive metabolism of dihydroergotamine especially to the main metabolite 8'-hydroxydihydroergotamine. The assay was successfully applied for more than one year to the determination of plasma and urine concentrations of dihydroergotamine after parenteral administration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3654884     DOI: 10.1016/0378-4347(87)80125-1

Source DB:  PubMed          Journal:  J Chromatogr


  2 in total

1.  Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjects.

Authors:  P A Wyss; J Rosenthaler; E Nüesch; W H Aellig
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Ergot alkaloids--sources, structures and analytical methods.

Authors:  M Flieger; M Wurst; R Shelby
Journal:  Folia Microbiol (Praha)       Date:  1997       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.